FDA is again being pulled into the drug pricing debate, this time by insurance companies with a report suggests that drugmakers may be exploiting orphan drug designation for economic gain with the non-orphan use of these treatments.
According to the report by America's Health Insurance Plans (AHIP), drugs being used primarily for the treatment of non-orphan indications...






